Cargando…

Observer-masked trial comparing efficacy of topical olopatadine (0.1%), bepotastine (1.5%), and alcaftadine (0.25%) in mild to moderate allergic conjunctivitis

PURPOSE: With increasing environmental pollution, the incidence of allergic conjunctivitis is increasing. Newer anti-allergic medications with combined anti-histaminic and mast cell stabilization action can help reducing the use of topical steroids for milder form of disease. There is no study direc...

Descripción completa

Detalles Bibliográficos
Autores principales:	Dudeja, Lakshey, Janakiraman, Anuja, Dudeja, Ishani, Sane, Kaustubh, Babu, Manohar
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Wolters Kluwer - Medknow 2019
Materias:	Original Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6727736/ https://www.ncbi.nlm.nih.gov/pubmed/31436181 http://dx.doi.org/10.4103/ijo.IJO_2112_18

Ejemplares similares

Comparative analysis of safety and efficacy of Alcaftadine 0.25%, Olopatadine hydrochloride 0.2% and Bepotastine besilate 1.5% in allergic conjunctivitis
por: Ayyappanavar, Shruti, et al.
Publicado: (2021)

Ocular argyrosis: A case with silver deposits in cornea and lens
por: Dudeja, Lakshey, et al.
Publicado: (2019)

Evaluation of alcaftadine 0.25% ophthalmic solution in acute allergic conjunctivitis at 15 minutes and 16 hours after instillation versus placebo and olopatadine 0.1%
por: Greiner, Jack V, et al.
Publicado: (2011)

Ocular Itch Relief with Alcaftadine 0.25% Versus Olopatadine 0.2% in Allergic Conjunctivitis: Pooled Analysis of Two Multicenter Randomized Clinical Trials
por: McLaurin, Eugene B., et al.
Publicado: (2014)

A multicenter evaluation of the efficacy and duration of action of alcaftadine 0.25% and olopatadine 0.2% in the conjunctival allergen challenge model
por: Ackerman, Stacey, et al.
Publicado: (2013)

Update and clinical utility of alcaftadine ophthalmic solution 0.25% in the treatment of allergic conjunctivitis
por: Chigbu, DeGaulle I, et al.
Publicado: (2015)

Efficacy of 0.05% epinastine and 0.1% olopatadine for allergic conjunctivitis as seasonal and preseasonal treatment
por: Mizoguchi, Takanori, et al.
Publicado: (2017)

Comparison of effects of alcaftadine and olopatadine on conjunctival epithelium and eosinophil recruitment in a murine model of allergic conjunctivitis
por: Ono, Santa J, et al.
Publicado: (2011)

Are we treating the effect and neglecting the cause of keratoconus?
por: Dudeja, Lakshey, et al.
Publicado: (2020)

To evaluate the efficacy and safety of olopatadine 0.1% ophthalmic solution and bepotastine 1.5% ophthalmic solution in patients with vernal keratoconjunctivitis in a tertiary care hospital
por: Sruthi, Vadlakonda, et al.
Publicado: (2020)

Allergic contact dermatitis of both eyes caused by alcaftadine 0.25%: a case report
por: Kim, Jae Hyuk, et al.
Publicado: (2019)

Effect of alcaftadine 0.25% on ocular itch associated with seasonal or perennial allergic conjunctivitis: a pooled analysis of two multicenter randomized clinical trials
por: Ciolino, Joseph B, et al.
Publicado: (2015)

Efficacy and Toxicity Evaluation of Bepotastine Besilate 1.5% Preservative-Free Eye Drops Vs Olopatadine Hydrochloride 0.2% Bak-Preserved Eye Drops in Patients with Allergic Conjunctivitis
por: Marini, María Cecilia, et al.
Publicado: (2023)

Comparative efficacy of bepotastine besilate 1.5% ophthalmic solution versus olopatadine hydrochloride 0.2% ophthalmic solution evaluated by patient preference
por: McCabe, Craig F, et al.
Publicado: (2012)

Efficacy of olopatadine hydrochloride 0.1%, emedastine difumarate 0.05%, and loteprednol etabonate 0.5% for Chinese children with seasonal allergic conjunctivitis: a randomized vehicle‐controlled study
por: Liu, Rui‐fen, et al.
Publicado: (2016)

Commentary: Precision pulse capsulotomy: New technology for capsulorhexis
por: Dudeja, Lakshey
Publicado: (2018)

Commentary: Intracameral illumination for cataract surgery
por: Dudeja, Lakshey
Publicado: (2019)

Pooled analysis of two studies evaluating efficacy and safety of olopatadine hydrochloride 0.77% in patients with allergic conjunctivitis
por: McLaurin, Eugene, et al.
Publicado: (2017)

Critical appraisal of bepotastine in the treatment of ocular itching associated with allergic conjunctivitis
por: Wingard, Jeremy B, et al.
Publicado: (2011)

Treatment of allergic conjunctivitis with bepotastine besilate ophthalmic solution 1.5%
por: Bergmann, Mark T, et al.
Publicado: (2014)

Management of allergic conjunctivitis: an evaluation of the perceived comfort and therapeutic efficacy of olopatadine 0.2% and azelastine 0.05% from two prospective studies
por: Epstein, Arthur B, et al.
Publicado: (2009)

Evaluation of Photocatalytic Performance of Nano-Sized Sr(0.9)La(0.1)TiO(3) and Sr(0.25)Ca(0.25)Na(0.25)Pr(0.25)TiO(3) Ceramic Powders for Water Purification
por: Jovanoski Kostić, Aleksandra, et al.
Publicado: (2022)

Treatment of allergic conjunctivitis with olopatadine hydrochloride eye drops
por: Uchio, Eiichi
Publicado: (2008)

Efficacy and safety of olopatadine hydrochloride 0.77% in patients with allergic conjunctivitis using a conjunctival allergen-challenge model
por: Torkildsen, Gail, et al.
Publicado: (2015)

Sequence of events leading to diagnosis of keratoconus and its impact on quality of life
por: Dudeja, Lakshey, et al.
Publicado: (2021)

Topical Olopatadine Hydrochloride versus Ketotifen Fumarate for Allergic Conjunctivitis
por: Patel, Dharmistha, et al.
Publicado: (2018)

Cryochemically Processed Li(1+y)Mn(1.95)Ni(0.025)Co(0.025)O(4) (y = 0, 0.1) Cathode Materials for Li-Ion Batteries
por: Normakhmedov, Ofok O., et al.
Publicado: (2018)

Olopatadine ophthalmic solution suppresses substance P release in the conjunctivitis models
por: Tamura, Tadafumi
Publicado: (2012)

Comparison of olopatadine with ketotifen for allergic conjunctivitis: a meta-analysis study
por: Li, Shiyu, et al.
Publicado: (2023)

A Comparative Study of 0.25% Levobupivacaine, 0.25% Ropivacaine, and 0.25% Bupivacaine in Paediatric Single Shot Caudal Block
por: Sharma, Jagdeep, et al.
Publicado: (2018)

Bepotastine besilate ophthalmic solution 1.5% for alleviating nasal symptoms in patients with allergic conjunctivitis
por: Cavet, Megan E, et al.
Publicado: (2018)

Study of magnetic and electrical properties of Pr(0.65)Ca(0.25)Ba(0.1)MnO(3) manganite
por: Mleiki, Ali, et al.
Publicado: (2018)

Critical phenomena and estimation of the spontaneous magnetization from a mean field analysis of the magnetic entropy change in La(0.7)Ca(0.1)Pb(0.2)Mn(0.95)Al(0.025)Sn(0.025)O(3)
por: Dhahri, Khadija, et al.
Publicado: (2018)

Electrical conductivity and dielectric behaviour of nanocrystalline La(0.6)Gd(0.1)Sr(0.3)Mn(0.75)Si(0.25)O(3)
por: Dhahri, Ah, et al.
Publicado: (2018)

The effectiveness of olopatadine hydrochloride eye drops for allergic conjunctivitis: Protocol for a systematic review
por: Zi, Yingxin, et al.
Publicado: (2020)

Hydrothermal Synthesis and Crystal Structure of a Novel Bismuth Oxide: (K(0.2)Sr(0.8))(Na(0.01)Ca(0.25)Bi(0.74))O(3)
por: Hossain, Khandaker Monower, et al.
Publicado: (2021)

A case report of allergic blepharoconjunctivis to alcaftadine
por: Sandrin, Leda Das Neves Almeida
Publicado: (2015)

Effect of strontium on Nd doped Ba(1−)(x)Sr(x)Ce(0.65)Zr(0.25)Nd(0.1)O(3−)(δ) proton conductor as an electrolyte for solid oxide fuel cells
por: Madhuri Sailaja, J., et al.
Publicado: (2017)

Projected 24-hour post-dose ocular itching scores post-treatment with olopatadine 0.7% versus 0.2%
por: Fidler, Matthew L., et al.
Publicado: (2018)

Peculiar Properties of the La(0.25)Ba(0.25)Sr(0.5)Co(0.8)Fe(0.2)O(3−δ) Perovskite as Oxygen Reduction Electrocatalyst
por: Aliotta, Chiara, et al.
Publicado: (2023)

Cannot write session to /tmp/vufind_sessions/sess_l8npb4o9plbgvai51m1lbb686k